Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

Glomerulonephritis Clinical Trial

Official title:

An Open-label, Phase 2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 in Subjects With IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05517980
• Other study ID #: KP104-203
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: August 2023
• Est. completion date: September 2025

Study information

• Verified date: August 2023
• Source: Kira Pharmacenticals (US), LLC.
• Contact: Study Director
• Email: privacy[@]kirapharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of KP104 in participants with IgAN and C3G. The study will start with enrolling the IgAN cohort. Approximately 42 participants with IgAN will be enrolled in 2 stages: Stage 1 will be used to collect safety, immunogenicity, PK, and PD data to select the optimal biologic dose (OBD) of KP104 for IgAN, as well as to preliminarily explore the effect of KP104 on C3G. Stage 2 will be used to collect safety, immunogenicity, PK, PD, and efficacy data at the OBD dose of KP104 for IgAN and C3G. As soon as the OBD for IgAN is determined, eligible participants with C3G will be enrolled and dosed at the OBD for IgAN for a minimum of 48 weeks for weekly maintenance dosing and a minimum of 47 weeks for biweekly maintenance dosing. Approximately 10 participants with C3G will be enrolled.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 52
• Est. completion date: September 2025
• Est. primary completion date: September 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Weight of >35 kilograms (kg) at Screening
• Body mass index (BMI) of <35 kilograms per square meter (kg/m^2)
• UPCR >1.0 grams per gram (g/g) by 24-hour urine collection at Screening
• Documented diagnosis and clinical status of IgAN or C3G as follows:

IgAN:

• Diagnosis of IgAN verified by biopsy taken within the past 3 years prior to enrolment.
• On stable regimen of angiotensin converting enzyme or angiotensin blocking agents for 12 weeks and/or sodium-glucose cotransporter-2 (SGLT2) inhibitors for 6 weeks at Screening

C3G:

• Diagnosis of C3G verified by biopsy taken within the past 3 years prior to enrolment.
• On stable regimen of angiotensin converting enzyme or angiotensin blocking agents for 12 weeks and/or SGLT2 inhibitors for 6 weeks at Screening
• Females of childbearing potential and males must practice effective contraception from Screening until 28 days after the end of study (EOS) visit.
• Females of childbearing potential must have a negative pregnancy test at Screening and within 1 day prior to dosing of study drug

Exclusion Criteria:

• Any clinically significant, poorly controlled underlying illness other than IgAN or C3G, as determined by the investigator
• Treatment of any infection with IV (within 30 days of Screening) or oral (within 14 days of Screening) antibiotics, antivirals, or antifungals
• History of infections with encapsulated organisms
• History of untreated tuberculosis
• Positive serology for hepatitis C virus (HCV) ribonucleic acid (RNA) or human immunodeficiency virus (HIV) at Screening
• History of bone marrow or stem cell transplantation
• Absolute neutrophil count (ANC) <500 cells per microliter (cells/µL)
• eGFR <30 milliliters per minute per 1.73 square meter (mL/min/1.73 m^2) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
• Presence of crescent formation in >50 percent (%) of glomeruli assessed on renal biopsy
• Nephrotic syndrome defined as presence of substantial proteinuria (> 3.5 g/24 hours), hypoalbuminemia (< 30 grams per liter [g/L]), and edema/hyperlipidemia. Nephrotic range proteinuria alone is acceptable.
• Rapidly progressive glomerulonephritis, defined as a fall in eGFR of > 30 mL/min/1.73 m^2 within 24 weeks prior to the Screening Visit
• Receiving renal replacement therapy or anticipated to require renal replacement therapy during the duration of the study NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Related Conditions & MeSH terms

• Glomerulonephritis

Intervention

Drug:
• KP104
Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Kira Pharmacenticals (US), LLC.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent change from Baseline in 24-hour urinary protein creatinine ratio (UPCR) at Week 24 (C3G) for participants in Stage 2	The UPCR will be calculated as percent change in protein (Pr)/ Creatinine (Cr).	Baseline and at Week 24
Secondary	Number of participants reporting Treatment-Emergent Adverse Events (TEAEs)	An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease or any worsening of a pre-existing condition temporally associated with the use of a study drug, whether or not related to study drug. A TEAE is defined as any AE that started or worsened in severity on or after the first dose of study treatment.	Up to 56 Weeks
Secondary	Number of participants reporting Treatment-Emergent Serious Adverse Events (TESAEs)	A TESAE is defined as a serious AE (SAE) that started or worsened in severity on or after the first dose of study treatment.	Up to 56 Weeks
Secondary	Number of participants reporting AEs of Special Interest (AESIs)	An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease or any worsening of a pre-existing condition temporally associated with the use of a study drug, whether or not related to study drug. Number of participants with AESIs including infections and local or systemic administration reactions will be assessed.	Up to 56 Weeks
Secondary	Maximum concentration (Cmax) of KP104	Blood samples will collected at indicated timepoints to assess Cmax.	At Baseline (Day 1), Days 8, 15, 22, 29, 43, 57, 85, 169, 253, 337, 365 and 395
Secondary	Trough concentration (Ctrough) of KP104 at steady state	Blood samples will collected at indicated timepoints to assess Ctrough.	At Baseline (Day 1), Days 8, 15, 22, 29, 43, 57, 85, 169, 253, 337, 365 and 395
Secondary	Change from Baseline in estimated glomerular filtration rate (eGFR) at Week 24 (C3G) for participants in Stage 2		Baseline and at Week 24